Click for best price
Chemotherapy Induced Acral Erythema HFoot Syndrome Treatment Market Size, Share 2022
Acral erythema, also called as hand-foot syndrome or palmar-plantar erythrodysesthesia, is characterized by swelling, redness, paraesthesia (numbness) and desquamation (skin peeling) of palms, soles and rarely on knees and elbow. Acryl erythema is an adverse drug reaction which typically appear after several months of treatment with chemotherapeutic agents, gemcitabine and fluorouracil being the most common drugs causing reaction. Chemotherapy induced acryl erythema is a dose dependent condition, regression of which can be achieved by discontinuation of chemotherapy or by dose reduction. Treatment for chemotherapy induced acryl erythema includes symptomatic treatment with analgesics and antihistaminic drugs to reduce pain and edema.
This report contains market size and forecasts of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment in Global, including the following market information:
Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Analgesics Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment include Taro, Oceanside Pharmaceuticals, Pfizer, Novartis, A-S Medication Solutions, Preferred Pharmaceuticals, Syntex Pharmaceuticals, Valeant Canada and Technilab Pharma and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Segment Percentages, by Type, 2021 (%)
Analgesics
Anti-Inflammatory And Anti-Edematous Agents
Antihistaminic
NSAIDs
Oral/Topical Glucocorticoids
Pyridoxine (Vitamin B6)
Others
Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Segment Percentages, by Application, 2021 (%)
Pharmacy And Drugstores
Hospital Pharmacy
Online Drug Stores
Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Taro
Oceanside Pharmaceuticals
Pfizer
Novartis
A-S Medication Solutions
Preferred Pharmaceuticals
Syntex Pharmaceuticals
Valeant Canada
Technilab Pharma
Allergan
| Report Attributes |
Report Details |
| Report Title |
Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market - Global Outlook and Forecast 2022-2028 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
65 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Introduction to Research & Analysis Reports
1.1 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Overall Market Size
2.1 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size: 2021 VS 2028
2.2 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size, Prospects & Forecasts: 2017-2028
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Players in Global Market
3.2 Top Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Companies Ranked by Revenue
3.3 Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue by Companies
3.4 Top 3 and Top 5 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Companies in Global Market, by Revenue in 2021
3.5 Global Companies Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Product Type
3.6 Tier 1, Tier 2 and Tier 3 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Players in Global Market
3.6.1 List of Global Tier 1 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Companies
3.6.2 List of Global Tier 2 and Tier 3 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Companies
4 Market Sights by Product
4.1 Overview
4.1.1 by Type - Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size Markets, 2021 & 2028
4.1.2 Analgesics
4.1.3 Anti-Inflammatory And Anti-Edematous Agents
4.1.4 Antihistaminic
4.1.5 NSAIDs
4.1.6 Oral/Topical Glucocorticoids
4.1.7 Pyridoxine (Vitamin B6)
4.1.8 Others
4.2 By Type - Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue & Forecasts
4.2.1 By Type - Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, 2017-2022
4.2.2 By Type - Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, 2023-2028
4.2.3 By Type - Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue Market Share, 2017-2028
5 Sights by Application
5.1 Overview
5.1.1 By Application - Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size, 2021 & 2028
5.1.2 Pharmacy And Drugstores
5.1.3 Hospital Pharmacy
5.1.4 Online Drug Stores
5.2 By Application - Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue & Forecasts
5.2.1 By Application - Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, 2017-2022
5.2.2 By Application - Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, 2023-2028
5.2.3 By Application - Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue Market Share, 2017-2028
6 Sights by Region
6.1 By Region - Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size, 2021 & 2028
6.2 By Region - Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue & Forecasts
6.2.1 By Region - Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, 2017-2022
6.2.2 By Region - Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, 2023-2028
6.2.3 By Region - Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue Market Share, 2017-2028
6.3 North America
6.3.1 By Country - North America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, 2017-2028
6.3.2 US Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size, 2017-2028
6.3.3 Canada Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size, 2017-2028
6.3.4 Mexico Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size, 2017-2028
6.4 Europe
6.4.1 By Country - Europe Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, 2017-2028
6.4.2 Germany Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size, 2017-2028
6.4.3 France Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size, 2017-2028
6.4.4 U.K. Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size, 2017-2028
6.4.5 Italy Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size, 2017-2028
6.4.6 Russia Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size, 2017-2028
6.4.7 Nordic Countries Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size, 2017-2028
6.4.8 Benelux Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size, 2017-2028
6.5 Asia
6.5.1 By Region - Asia Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, 2017-2028
6.5.2 China Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size, 2017-2028
6.5.3 Japan Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size, 2017-2028
6.5.4 South Korea Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size, 2017-2028
6.5.5 Southeast Asia Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size, 2017-2028
6.5.6 India Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size, 2017-2028
6.6 South America
6.6.1 By Country - South America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, 2017-2028
6.6.2 Brazil Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size, 2017-2028
6.6.3 Argentina Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size, 2017-2028
6.7 Middle East & Africa
6.7.1 By Country - Middle East & Africa Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, 2017-2028
6.7.2 Turkey Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size, 2017-2028
6.7.3 Israel Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size, 2017-2028
6.7.4 Saudi Arabia Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size, 2017-2028
6.7.5 UAE Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size, 2017-2028
7 Players Profiles
7.1 Taro
7.1.1 Taro Corporate Summary
7.1.2 Taro Business Overview
7.1.3 Taro Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Major Product Offerings
7.1.4 Taro Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue in Global Market (2017-2022)
7.1.5 Taro Key News
7.2 Oceanside Pharmaceuticals
7.2.1 Oceanside Pharmaceuticals Corporate Summary
7.2.2 Oceanside Pharmaceuticals Business Overview
7.2.3 Oceanside Pharmaceuticals Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Major Product Offerings
7.2.4 Oceanside Pharmaceuticals Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue in Global Market (2017-2022)
7.2.5 Oceanside Pharmaceuticals Key News
7.3 Pfizer
7.3.1 Pfizer Corporate Summary
7.3.2 Pfizer Business Overview
7.3.3 Pfizer Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Major Product Offerings
7.3.4 Pfizer Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue in Global Market (2017-2022)
7.3.5 Pfizer Key News
7.4 Novartis
7.4.1 Novartis Corporate Summary
7.4.2 Novartis Business Overview
7.4.3 Novartis Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Major Product Offerings
7.4.4 Novartis Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue in Global Market (2017-2022)
7.4.5 Novartis Key News
7.5 A-S Medication Solutions
7.5.1 A-S Medication Solutions Corporate Summary
7.5.2 A-S Medication Solutions Business Overview
7.5.3 A-S Medication Solutions Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Major Product Offerings
7.5.4 A-S Medication Solutions Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue in Global Market (2017-2022)
7.5.5 A-S Medication Solutions Key News
7.6 Preferred Pharmaceuticals
7.6.1 Preferred Pharmaceuticals Corporate Summary
7.6.2 Preferred Pharmaceuticals Business Overview
7.6.3 Preferred Pharmaceuticals Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Major Product Offerings
7.6.4 Preferred Pharmaceuticals Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue in Global Market (2017-2022)
7.6.5 Preferred Pharmaceuticals Key News
7.7 Syntex Pharmaceuticals
7.7.1 Syntex Pharmaceuticals Corporate Summary
7.7.2 Syntex Pharmaceuticals Business Overview
7.7.3 Syntex Pharmaceuticals Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Major Product Offerings
7.7.4 Syntex Pharmaceuticals Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue in Global Market (2017-2022)
7.7.5 Syntex Pharmaceuticals Key News
7.8 Valeant Canada
7.8.1 Valeant Canada Corporate Summary
7.8.2 Valeant Canada Business Overview
7.8.3 Valeant Canada Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Major Product Offerings
7.8.4 Valeant Canada Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue in Global Market (2017-2022)
7.8.5 Valeant Canada Key News
7.9 Technilab Pharma
7.9.1 Technilab Pharma Corporate Summary
7.9.2 Technilab Pharma Business Overview
7.9.3 Technilab Pharma Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Major Product Offerings
7.9.4 Technilab Pharma Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue in Global Market (2017-2022)
7.9.5 Technilab Pharma Key News
7.10 Allergan
7.10.1 Allergan Corporate Summary
7.10.2 Allergan Business Overview
7.10.3 Allergan Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Major Product Offerings
7.10.4 Allergan Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue in Global Market (2017-2022)
7.10.5 Allergan Key News
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Opportunities & Trends in Global Market
Table 2. Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Drivers in Global Market
Table 3. Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Restraints in Global Market
Table 4. Key Players of Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment in Global Market
Table 5. Top Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Players in Global Market, Ranking by Revenue (2021)
Table 6. Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue by Companies, (US$, Mn), 2017-2022
Table 7. Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue Share by Companies, 2017-2022
Table 8. Global Companies Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Product Type
Table 9. List of Global Tier 1 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Companies, Revenue (US$, Mn) in 2021 and Market Share
Table 11. By Type ? Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, (US$, Mn), 2021 & 2028
Table 12. By Type - Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue in Global (US$, Mn), 2017-2022
Table 13. By Type - Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue in Global (US$, Mn), 2023-2028
Table 14. By Application ? Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, (US$, Mn), 2021 & 2028
Table 15. By Application - Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue in Global (US$, Mn), 2017-2022
Table 16. By Application - Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue in Global (US$, Mn), 2023-2028
Table 17. By Region ? Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, (US$, Mn), 2021 & 2028
Table 18. By Region - Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue (US$, Mn), 2017-2022
Table 19. By Region - Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue (US$, Mn), 2023-2028
Table 20. By Country - North America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, (US$, Mn), 2017-2022
Table 21. By Country - North America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, (US$, Mn), 2023-2028
Table 22. By Country - Europe Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, (US$, Mn), 2017-2022
Table 23. By Country - Europe Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, (US$, Mn), 2023-2028
Table 24. By Region - Asia Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, (US$, Mn), 2017-2022
Table 25. By Region - Asia Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, (US$, Mn), 2023-2028
Table 26. By Country - South America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, (US$, Mn), 2017-2022
Table 27. By Country - South America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, (US$, Mn), 2023-2028
Table 28. By Country - Middle East & Africa Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, (US$, Mn), 2017-2022
Table 29. By Country - Middle East & Africa Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, (US$, Mn), 2023-2028
Table 30. Taro Corporate Summary
Table 31. Taro Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Product Offerings
Table 32. Taro Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue (US$, Mn), (2017-2022)
Table 33. Oceanside Pharmaceuticals Corporate Summary
Table 34. Oceanside Pharmaceuticals Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Product Offerings
Table 35. Oceanside Pharmaceuticals Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue (US$, Mn), (2017-2022)
Table 36. Pfizer Corporate Summary
Table 37. Pfizer Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Product Offerings
Table 38. Pfizer Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue (US$, Mn), (2017-2022)
Table 39. Novartis Corporate Summary
Table 40. Novartis Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Product Offerings
Table 41. Novartis Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue (US$, Mn), (2017-2022)
Table 42. A-S Medication Solutions Corporate Summary
Table 43. A-S Medication Solutions Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Product Offerings
Table 44. A-S Medication Solutions Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue (US$, Mn), (2017-2022)
Table 45. Preferred Pharmaceuticals Corporate Summary
Table 46. Preferred Pharmaceuticals Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Product Offerings
Table 47. Preferred Pharmaceuticals Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue (US$, Mn), (2017-2022)
Table 48. Syntex Pharmaceuticals Corporate Summary
Table 49. Syntex Pharmaceuticals Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Product Offerings
Table 50. Syntex Pharmaceuticals Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue (US$, Mn), (2017-2022)
Table 51. Valeant Canada Corporate Summary
Table 52. Valeant Canada Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Product Offerings
Table 53. Valeant Canada Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue (US$, Mn), (2017-2022)
Table 54. Technilab Pharma Corporate Summary
Table 55. Technilab Pharma Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Product Offerings
Table 56. Technilab Pharma Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue (US$, Mn), (2017-2022)
Table 57. Allergan Corporate Summary
Table 58. Allergan Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Product Offerings
Table 59. Allergan Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue (US$, Mn), (2017-2022)
List of Figures
Figure 1. Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Segment by Type in 2021
Figure 2. Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Segment by Application in 2021
Figure 3. Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Overview: 2021
Figure 4. Key Caveats
Figure 5. Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Market Size: 2021 VS 2028 (US$, Mn)
Figure 6. Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, 2017-2028 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue in 2021
Figure 8. By Type - Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue Market Share, 2017-2028
Figure 9. By Application - Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue Market Share, 2017-2028
Figure 10. By Region - Global Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue Market Share, 2017-2028
Figure 11. By Country - North America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue Market Share, 2017-2028
Figure 12. US Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, (US$, Mn), 2017-2028
Figure 13. Canada Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, (US$, Mn), 2017-2028
Figure 14. Mexico Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, (US$, Mn), 2017-2028
Figure 15. By Country - Europe Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue Market Share, 2017-2028
Figure 16. Germany Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, (US$, Mn), 2017-2028
Figure 17. France Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, (US$, Mn), 2017-2028
Figure 18. U.K. Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, (US$, Mn), 2017-2028
Figure 19. Italy Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, (US$, Mn), 2017-2028
Figure 20. Russia Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, (US$, Mn), 2017-2028
Figure 21. Nordic Countries Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, (US$, Mn), 2017-2028
Figure 22. Benelux Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, (US$, Mn), 2017-2028
Figure 23. By Region - Asia Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue Market Share, 2017-2028
Figure 24. China Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, (US$, Mn), 2017-2028
Figure 25. Japan Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, (US$, Mn), 2017-2028
Figure 26. South Korea Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, (US$, Mn), 2017-2028
Figure 27. Southeast Asia Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, (US$, Mn), 2017-2028
Figure 28. India Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, (US$, Mn), 2017-2028
Figure 29. By Country - South America Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue Market Share, 2017-2028
Figure 30. Brazil Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, (US$, Mn), 2017-2028
Figure 31. Argentina Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, (US$, Mn), 2017-2028
Figure 32. By Country - Middle East & Africa Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue Market Share, 2017-2028
Figure 33. Turkey Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, (US$, Mn), 2017-2028
Figure 34. Israel Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, (US$, Mn), 2017-2028
Figure 35. Saudi Arabia Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, (US$, Mn), 2017-2028
Figure 36. UAE Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue, (US$, Mn), 2017-2028
Figure 37. Taro Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 38. Oceanside Pharmaceuticals Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 39. Pfizer Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 40. Novartis Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 41. A-S Medication Solutions Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 42. Preferred Pharmaceuticals Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 43. Syntex Pharmaceuticals Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 44. Valeant Canada Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 45. Technilab Pharma Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
Figure 46. Allergan Chemotherapy Induced Acral Erythema (Hand-Foot Syndrome) Treatment Revenue Year Over Year Growth (US$, Mn) & (2017-2022)
